08 May Stockhead – ScoPo’s health powerplays: How to invest in COVID-19
In an article for Stockhead, Morgans senior analyst Scott Power discusses how Atomo’s rapid test for COVID-19 enabled it to list on the ASX in April. Read the full article > ...
04 May Lawyers Weekly: Atomo raises $30m in IPO
Lawyers Weekly discusses Atomo Diagnostics’ $30 million IPO and ASX listing as well its integrated rapid diagnostic test (RDT) devices. Read the full article >...
23 Apr Bloomberg: Biotech Listings Help Prop Up Anemic U.S. IPO Market
An article in Bloomberg talks about Atomo’s rapid share price rise after its ASX listing in a broader piece on US IPOs amid COVID-19. Read the full article > ...
18 Apr Kalkine Media: Atomo Diagnostics – The Shining IPO on ASX Amid COVID 19?
An article on the Kalkine Media website discusses Atomo’s ASX listing, its integrated rapid diagnostic test devices and agreement with NG Biotech for the supply of devices for the rapid blood-based testing of antibodies produced in response to COVID 19. Read the full article > ...
17 Apr WSJ.com: Rapid Coronavirus Test Device Maker’s Shares Soar in IPO
An article in WSJ.com looks at Atomo’s strong ASX debut and how its device could produce blood-test results in 15 minutes for COVID-19 testing. Read the full article > ...
17 Apr Founder and CEO John Kelly interviewed by David Koch of Ausbiz
CEO John Kelly speaks to David Koch of Ausbiz about the Atomo’s successful ASX listing and support from blue-chip investors. [embed]https://assets.ausbiz.live/assets/e5a23332-74f7-432d-8e99-23fa1907814b/MP4/vimondio_video_1280x720_2000.mp4[/embed]...
16 Apr MEDIA RELEASE: Atomo Diagnostics to list on ASX after successful IPO and virtual bell ringing ceremony
SYDNEY Australia 16 April 2020– Following an oversubscribed initial public offering and the first ASX virtual bell ringing listing, trading of shares in Australian rapid blood test company Atomo Diagnostics Limited (Atomo) will commence on the Australian Securities Exchange (ASX) today under the ticker code...
16 Apr AAP: COVID-19 testmaker Atomo pops on ASX debut
Founder and CEO John Kelly speaks to AAP about the company’s ASX debut and the company’s unique position to make a major impact within the COVID-19 environment. The article was syndicated across a range of national, metropolitan and regional press, 7 News.com.au, 9Finance and Yahoo7...
16 Apr Atomo’s ASX listing featured across Nine Entertainment press
Atomo’s strong perfromance on its first day of being an ASX listed company was featured in markets blogs in the SMH, The Age, Brisbane Times and WA Today. Read the full article > ...
16 Apr Trading of shares in Atomo commences on the ASX today
Following an oversubscribed initial public offering and the first ASX virtual bell ringing listing, trading of shares in Atomo Diagnostics Limited commences on the Australian Securities Exchange (ASX) today under the ticker code AT1. Strong institutional and retail investor demand has led to the company raising...
01 Apr Atomo secures significant European sales agreement and announces the early close of its oversubscribed $30 million Initial Public Offer
Atomo Diagnostics announced today that it has entered into a binding supply agreement with French diagnostics company, NG Biotech, SAS (NG Biotech), for the supply of Atomo’s integrated blood test devices to NG Biotech to use for its blood-based rapid test to detect COVID-19. Under the...
01 Apr MEDIA RELEASE: Atomo secures significant European sales agreement for rapid COVID-19 tests
$30m Initial Public Offer closes oversubscribed SYDNEY Australia, 01 April 2020: Australian rapid blood test company Atomo Diagnostics Limited (ACN 142 925 684) said today it has entered into a binding supply agreement with French diagnostics company, NG Biotech, SAS (NG Biotech), for the supply of Atomo’s...